Goldman Sachs Starts ISIS Pharmaceuticals (ISIS) at Neutral; Sees 30% Downside if SMN-Rx Fails
Tweet Send to a Friend
Goldman Sachs initiates coverage on ISIS Pharmaceuticals (NASDAQ: ISIS) with a Neutral rating and $26 price target.
While analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
While analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
